Dr Alan Richardson
Research in Alan’s group mostly focuses on identifying metabolic processes which can be targeted to treat cancer, in particular ovarian and breast cancer. Current areas of interest include protein prenylation and the use of statins, branched chain amino acid metabolism and autophagy. The overarching goals of research in this group are to identify drug candidates for clinical trials but at the same time uncover the underlying biological rationale for therapy. In many cases, this includes the evaluation of drug combinations to help overcome resistance to single agent therapies.